ASM
TVGNW icon

ATW SPAC Management’s Tevogen Bio Warrant TVGNW Stock Holding History

ATW SPAC Management’s Portfolio TVGNW Stock Details TVGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$504 – 181
2024
Q2 		$504 Hold
25,000
– – ﹤0.01% 160
2024
Q1 		$2.06K Hold
25,000
– – ﹤0.01% 160
2023
Q4 		$1K Buy
+25,000
New +$1.01K ﹤0.01% 169

Other funds holding TVGNW

FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

ATW SPAC Management's TVGNW Position: Q3 2025 in Review

ATW SPAC Management held its Tevogen Bio Warrant (TVGNW) position steady in Q3 2025 at 25,000 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #149.

ATW SPAC Management first reported a position in TVGNW in Q1 2022 and has held it in 12 quarters since. The position peaked at $4K in Q2 2022. 35 funds tracked by Wall St. Rank hold TVGNW as of Q3 2025.

  • ATW SPAC Management held 25,000 shares of Tevogen Bio Warrant worth $1.39K as of Q3 2025.
  • ATW SPAC Management left its Tevogen Bio Warrant share count unchanged in Q3 2025.
  • Tevogen Bio Warrant made up ﹤0.01% of ATW SPAC Management's portfolio in Q3 2025, its #149 holding.
  • ATW SPAC Management first reported a position in Tevogen Bio Warrant in Q1 2022 and has held it in 12 quarters since.
  • ATW SPAC Management's Tevogen Bio Warrant position peaked at $4K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Tevogen Bio Warrant as of Q3 2025.

Based on ATW SPAC Management's 13F filing for Q3 2025, filed 12 Nov 2025.